InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 13.93
+0.43 (3.19%)
May 7, 2026, 4:08 PM HKT
InnoCare Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,520 | 2,373 | 1,008 | 736.99 | 625.4 | 1,043 |
Other Revenue | 2.16 | 2.16 | 1.8 | 1.55 | - | - |
| 2,522 | 2,375 | 1,009 | 738.54 | 625.4 | 1,043 | |
Revenue Growth (YoY) | 105.92% | 135.27% | 36.68% | 18.09% | -40.04% | 76368.70% |
Cost of Revenue | 217.94 | 191.28 | 138.55 | 128.44 | 143.4 | 65.67 |
Gross Profit | 2,304 | 2,184 | 870.9 | 610.1 | 482.01 | 977.37 |
Selling, General & Admin | 764.78 | 759.11 | 588.49 | 551.01 | 613.27 | 436.89 |
Research & Development | 973.17 | 951.62 | 814.61 | 757.25 | 639.14 | 721.58 |
Other Operating Expenses | 18.79 | 20.19 | -12.23 | -26.76 | 7 | 1.42 |
Operating Expenses | 1,757 | 1,731 | 1,392 | 1,282 | 1,259 | 1,160 |
Operating Income | 547.17 | 452.3 | -521.47 | -671.67 | -777.4 | -182.53 |
Interest Expense | -54.13 | -54.13 | -33.79 | -35.21 | -17.05 | -2.64 |
Interest & Investment Income | 169.84 | 174.92 | 178.71 | 197.9 | 145.4 | 135.21 |
Earnings From Equity Investments | - | - | - | - | -9.71 | -0.6 |
Currency Exchange Gain (Loss) | 31.85 | 31.85 | -43.65 | -87.84 | - | 57.14 |
Other Non Operating Income (Expenses) | -3.19 | -0.94 | -1.91 | 6.57 | -244.93 | 17.59 |
EBT Excluding Unusual Items | 691.54 | 604 | -422.12 | -590.24 | -903.68 | 24.16 |
Gain (Loss) on Sale of Investments | 3.9 | 3.14 | -30.46 | -53.96 | 6.56 | 6.73 |
Gain (Loss) on Sale of Assets | - | 0 | - | - | - | - |
Asset Writedown | 0.14 | - | -0.01 | - | - | - |
Other Unusual Items | 48.6 | 48.6 | - | - | 3.4 | -51.01 |
Pretax Income | 744.2 | 655.74 | -452.59 | -644.21 | -893.73 | -20.12 |
Income Tax Expense | 12.04 | 11.56 | 0.26 | 1.43 | - | 46.56 |
Earnings From Continuing Operations | 732.15 | 644.18 | -452.86 | -645.63 | -893.73 | -66.68 |
Minority Interest in Earnings | -1.84 | -1.72 | 12.22 | 14.37 | 7.13 | 2.13 |
Net Income | 730.32 | 642.47 | -440.63 | -631.26 | -886.59 | -64.55 |
Net Income to Common | 730.32 | 642.47 | -440.63 | -631.26 | -886.59 | -64.55 |
Shares Outstanding (Basic) | 1,682 | 1,691 | 1,695 | 1,706 | 1,480 | 1,366 |
Shares Outstanding (Diluted) | 1,682 | 1,691 | 1,695 | 1,706 | 1,480 | 1,366 |
Shares Change (YoY) | -0.97% | -0.24% | -0.67% | 15.31% | 8.29% | 41.21% |
EPS (Basic) | 0.43 | 0.38 | -0.26 | -0.37 | -0.60 | -0.05 |
EPS (Diluted) | 0.43 | 0.38 | -0.26 | -0.37 | -0.60 | -0.05 |
Free Cash Flow | -43.54 | 13.74 | -443.78 | -920.14 | -792.79 | -2.71 |
Free Cash Flow Per Share | -0.03 | 0.01 | -0.26 | -0.54 | -0.54 | -0.00 |
Gross Margin | 91.36% | 91.95% | 86.28% | 82.61% | 77.07% | 93.70% |
Operating Margin | 21.69% | 19.05% | -51.66% | -90.95% | -124.30% | -17.50% |
Profit Margin | 28.95% | 27.05% | -43.65% | -85.47% | -141.76% | -6.19% |
Free Cash Flow Margin | -1.73% | 0.58% | -43.96% | -124.59% | -126.76% | -0.26% |
EBITDA | 627.6 | 530.54 | -451.97 | -611.8 | -731.46 | -167.2 |
EBITDA Margin | 24.88% | 22.34% | -44.77% | -82.84% | -116.96% | -16.03% |
D&A For EBITDA | 80.43 | 78.24 | 69.5 | 59.87 | 45.94 | 15.33 |
EBIT | 547.17 | 452.3 | -521.47 | -671.67 | -777.4 | -182.53 |
EBIT Margin | 21.69% | 19.05% | -51.66% | -90.95% | -124.30% | -17.50% |
Effective Tax Rate | 1.62% | 1.76% | - | - | - | - |
Revenue as Reported | 2,375 | 2,375 | 1,009 | 738.54 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.